Drug Monograph
Minocycline
minocycline hydrochloride — brands include Minocin, Solodyn (ER for acne), Emrosi (ER for rosacea), Ximino
Pharmacokinetic Profile
Half-Life
11–24 h (average ~17 h)
Metabolism
Hepatic (~50%); CYP3A4 hydroxylation and N-demethylation
Protein Binding
70–76%
Bioavailability
90–100% (oral)
Volume of Distribution
0.14–0.7 L/kg
Clinical Information
Drug Class
Tetracycline antibiotic (second-generation)
Available Doses
50, 75, 100 mg capsules/tablets; 45–135 mg ER tablets (Solodyn); 40 mg ER capsules (Emrosi); 100 mg IV
Route
Oral, Intravenous, Topical
Renal Adjustment
Reduce dose in renal impairment (not fully characterised)
Hepatic Adjustment
Use with caution; hepatotoxicity reported
Pregnancy
Category D — avoid (tooth discoloration, bone growth inhibition, teratogenicity in animals)
Lactation
Excreted in breast milk; calcium binding may limit infant absorption; avoid prolonged use
Schedule / Legal Status
Prescription only (not a controlled substance)
Generic Available
Yes (immediate-release); brand-only for some ER formulations
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Moderate-to-severe inflammatory acne vulgaris (non-nodular) | ≥12 years (Solodyn ER) | Adjunctive (with topical agents) | FDA Approved |
| Rickettsial infections (RMSF, typhus, Q fever) | Adults and children >8 y | First-line or alternative | FDA Approved |
| Respiratory tract infections (CAP with atypical pathogens) | Adults | Monotherapy or combination | FDA Approved |
| Urogenital and rectal chlamydia | Adults | First-line or alternative | FDA Approved |
| Syphilis (when penicillin contraindicated) | Adults | Alternative | FDA Approved |
| Meningococcal carrier state eradication | Adults | Not for treatment of meningococcal infection | FDA Approved |
| Mycobacterium marinum skin infections | Adults | Monotherapy | FDA Approved |
| Uncomplicated gonorrhoea, chancroid, granuloma inguinale | Adults | Alternative | FDA Approved |
| Anthrax (including inhalational post-exposure) | All ages | First-line or combination | FDA Approved |
Minocycline is a second-generation tetracycline distinguished from doxycycline by its greater lipophilicity, superior CNS and skin penetration, and additional anti-inflammatory properties. These characteristics make it particularly valuable in dermatology (acne, rosacea) and in treating CNS-penetrating infections. However, its higher rate of vestibular side effects, risk of tissue pigmentation with prolonged use, and association with autoimmune syndromes have made doxycycline the generally preferred tetracycline for most infectious disease indications. Minocycline retains clinical importance against multidrug-resistant organisms, including some MRSA and carbapenem-resistant Acinetobacter baumannii strains.
Off-Label Uses
Rosacea (sub-antimicrobial dose): Emrosi (minocycline ER 40 mg once daily) is FDA-approved under a separate label for inflammatory lesions of rosacea. Evidence quality: High.
MRSA skin and soft tissue infections: Oral minocycline used as step-down therapy for susceptible MRSA when other options limited. Evidence quality: Moderate.
Carbapenem-resistant Acinetobacter baumannii: IV minocycline used as part of combination therapy for MDR gram-negative infections. Evidence quality: Moderate.
Rheumatoid arthritis: Some evidence supporting anti-inflammatory benefit as adjunctive therapy. Not widely adopted. Evidence quality: Low.
Nocardiosis: Alternative therapy, particularly for CNS involvement due to good CSF penetration. Evidence quality: Moderate.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| General infections (mild-moderate) | 200 mg loading (100 mg q12h) | 100 mg q12h | 400 mg/day | Can also give 100 mg followed by 50 mg q6h (FDA PI) IV: 200 mg loading, then 100 mg q12h; max 400 mg/day IV; switch to oral ASAP |
| Moderate-to-severe inflammatory acne (ER formulation) | ~1 mg/kg once daily | 1 mg/kg once daily | 135 mg daily | 12 weeks duration (Solodyn); weight-based dosing per table in PI Higher doses do not improve efficacy but increase vestibular AEs |
| Rosacea (sub-antimicrobial ER dose) | 40 mg once daily | 40 mg once daily | 40 mg once daily | Emrosi; sub-antimicrobial dose for anti-inflammatory effect |
| Chlamydial urethritis / cervicitis | 100 mg q12h | 100 mg q12h | 100 mg q12h | ≥7 days (FDA PI) |
| Syphilis (penicillin-allergic) | Standard dosage | Standard dosage | Standard dosage | 10–15 days with close serological follow-up (FDA PI) |
| Meningococcal carrier state eradication | 100 mg q12h | 100 mg q12h | 100 mg q12h | 5 days (FDA PI); not for treatment of meningococcal infection |
| Mycobacterium marinum skin infection | 100 mg q12h | 100 mg q12h | 100 mg q12h | 6–8 weeks; optimal dose not firmly established (FDA PI) |
| MDR Acinetobacter (IV, combination therapy) | 200 mg IV loading | 100 mg IV q12h | 400 mg/day | As part of combination regimen; switch to oral when feasible; monitor for thrombophlebitis |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| General infections (>8 y) | 4 mg/kg loading (day 1) | 2 mg/kg q12h | 100 mg q12h | FDA PI; do not exceed adult dose |
| Acne ER (≥12 y, Solodyn) | ~1 mg/kg once daily | 1 mg/kg once daily | 135 mg daily | Weight-based dosing; 12 weeks (Solodyn PI) |
Renal Impairment
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Renal impairment (CrCl <80 mL/min) | Reduce dose or extend interval | Individualize | 200 mg/day | PK not fully characterised in renal impairment (FDA PI); total daily dose should not exceed 200 mg. Not significantly removed by haemodialysis. |
Clinical Pearl: Weight-Based Dosing for Acne Prevents Vestibular Toxicity
The Solodyn ER formulation uses weight-based dosing at approximately 1 mg/kg/day specifically to minimise acute vestibular adverse events (dizziness, vertigo, ataxia). Phase 3 data showed that higher doses did not improve acne outcomes but significantly increased vestibular symptoms. The ER formulation also reduces peak-to-trough fluctuations, further lowering the rate of CNS-mediated side effects compared with immediate-release minocycline.
Pharmacology
Mechanism of Action
Minocycline exerts its bacteriostatic effect by reversibly binding to the 30S ribosomal subunit of susceptible bacteria, preventing aminoacyl-tRNA from attaching to the acceptor site and thereby blocking peptide chain elongation. This halts bacterial protein synthesis without directly killing the organism. Minocycline is the most lipophilic tetracycline, allowing it to cross the blood-brain barrier more effectively than doxycycline or tetracycline — a property that contributes to both its efficacy in CNS infections and its higher incidence of vestibular side effects. Beyond antimicrobial activity, minocycline has potent anti-inflammatory and immunomodulatory properties: it inhibits matrix metalloproteinases (MMPs), suppresses microglial activation, reduces nitric oxide production, and scavenges free radicals. These properties underpin its use in acne and rosacea at sub-antimicrobial doses and have generated research interest in neurodegenerative and autoimmune conditions.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | 90–100% bioavailable; Tmax 1.5–4 h (IR), 3.5 h (ER); food minimally affects absorption but divalent/trivalent cations (Ca, Mg, Fe, Al) reduce it via chelation | Can be taken with or without food; separate from antacids, iron, and calcium supplements by 2–3 hours |
| Distribution | Vd 0.14–0.7 L/kg; protein binding 70–76%; excellent CNS, skin, and saliva penetration; 5× more lipophilic than doxycycline; crosses blood-brain barrier | Best CNS penetration of all tetracyclines — effective for meningococcal carrier eradication and nocardiosis; high skin concentration supports acne efficacy; concentrates in sebum |
| Metabolism | ~50% hepatically metabolised; primary metabolite 9-hydroxyminocycline; two N-demethylated metabolites; CYP3A4 involvement | Greater hepatic metabolism than doxycycline; use with caution in hepatic impairment; potential for CYP3A4 interactions (though clinically limited) |
| Elimination | t½ 11–24 h (mean ~17 h); renal excretion 10–13% as unchanged drug; faecal excretion ~19%; not significantly removed by haemodialysis | Reduce dose in renal impairment (unlike doxycycline which requires no adjustment); twice-daily dosing for IR; once-daily for ER |
Side Effects
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | Up to 23% | Most common adverse effect in clinical trials. Distinguish persistent or worsening headache from intracranial hypertension. |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 5–10% | Taking with food reduces incidence. Less GI upset than with older tetracyclines. Not among the ≥5% AEs in Solodyn ER trials. |
| Dizziness / vertigo / ataxia (vestibular) | 1–10% | Unique to minocycline among tetracyclines. Dose-dependent; higher with immediate-release. Usually occurs in first days. ER formulation (Solodyn) reduces incidence to near-placebo levels (~9–10% vs 8–11% placebo). |
| Fatigue / malaise | Up to 9% | Reported in Solodyn Phase 3 trials at ≥5% incidence |
| Pruritus | ≥5% | Among the most commonly reported AEs in Solodyn acne trials |
| Diarrhea | 3–8% | Consider C. difficile if persistent or bloody |
| Vomiting | 3–5% | More common on empty stomach; food co-administration recommended |
| Photosensitivity | Rare (less than doxycycline) | Minocycline causes less photosensitivity than doxycycline, but cases have been reported. Sunscreen still advised. |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Tissue pigmentation (skin, mucosa, nails, sclera, teeth, bone, thyroid) | Dose- and duration-dependent; common with prolonged use | Months to years; may be irreversible | Blue-black or grey discoloration of skin, gums, nails, sclera, and thyroid. May be permanent. Discontinue if cosmetically unacceptable. Monitor thyroid with prolonged use. |
| Autoimmune syndromes (drug-induced lupus, autoimmune hepatitis, serum sickness-like, vasculitis) | Uncommon; more frequent than with other tetracyclines | Weeks to months | Discontinue immediately. Check ANA, LFTs. May require immunosuppressive therapy. Symptoms include fever, arthralgia, rash, hepatitis, myalgia. Fatalities reported. |
| Hepatotoxicity (including fulminant hepatic failure) | Rare; fatalities reported | Variable; may be autoimmune-mediated or direct | Discontinue immediately if jaundice, liver tenderness, or elevated LFTs. Post-marketing cases of irreversible drug-induced hepatitis reported with acne treatment. |
| Hypersensitivity syndrome (DRESS) | Rare; fatalities reported | 2–8 weeks | Immediate discontinuation; emergency treatment. Features: rash, eosinophilia, hepatitis, pneumonitis, nephritis, myocarditis, pericarditis. |
| Intracranial hypertension (pseudotumor cerebri) | Rare | Days to weeks | Discontinue minocycline. Ophthalmology referral for papilloedema assessment. Do not co-administer with isotretinoin or vitamin A. |
| Clostridioides difficile-associated diarrhea | Uncommon | During or up to 2 months after therapy | Stool C. difficile toxin assay; discontinue minocycline; treat with oral vancomycin or fidaxomicin |
| Severe skin reactions (SJS/TEN, erythema multiforme, fixed drug eruption) | Very rare | Days to weeks | Permanent discontinuation; do not re-challenge. Worsening severity upon re-exposure has been documented. |
| Thyroid discoloration and thyroid cancer | Very rare (post-marketing) | Prolonged use | Brown-black thyroid discoloration reported with prolonged courses. Thyroid cancer reported post-marketing. Monitor thyroid function with long-term use. |
| Tooth discoloration (yellow-grey-brown) | Common if used during tooth development | During developing dentition (pregnancy, children <8 y); also reported in adults with prolonged use | Avoid in pregnancy (2nd/3rd trimester) and children <8 y unless no alternative. Adult tooth staining reported with prolonged use and may be irreversible. |
Discontinuation
Discontinuation Rates
Solodyn ER (acne, 12 weeks)
~8% due to drug-related AEs (across long-term RCTs)
Top reasons: Vestibular symptoms (dizziness/vertigo), nausea, headache. Solodyn ER Phase 3 showed AE incidence similar to placebo, suggesting lower discontinuation with ER formulation.
Immediate-release (infections)
Higher than doxycycline
Top reasons: Vestibular AEs (dizziness, vertigo); GI intolerance; pigmentation with prolonged use. Systematic reviews consistently report more AEs with minocycline than doxycycline.
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Vestibular symptoms (dizziness, vertigo) | ~2–5% | More frequent with IR formulation; typically occurs in first 1–5 days |
| GI intolerance (nausea, vomiting) | ~2–3% | Reduced with food co-administration and ER formulation |
| Autoimmune/hypersensitivity reaction | <1% | More common with prolonged use (>3 months) |
Pigmentation: The Most Clinically Distinctive Side Effect
Minocycline causes dose- and duration-dependent blue-black or grey pigmentation of skin (particularly sun-exposed areas and scars), gums, nails, sclera, teeth, bones, and the thyroid gland. Three distinct pigmentation types have been described: Type I (blue-black in scars/inflammation), Type II (blue-grey on normal skin, often shins), and Type III (diffuse muddy-brown, usually sun-exposed). Type I and III typically fade after discontinuation, but Type II may be permanent. This effect is unique to minocycline among the tetracyclines and is the primary reason many dermatologists now prefer doxycycline for long-term acne treatment.
Drug Interactions
Minocycline shares the core tetracycline interaction profile — chelation with polyvalent cations, antagonism with bactericidal agents, and enhanced anticoagulant effects. Unlike doxycycline, minocycline undergoes approximately 50% hepatic metabolism via CYP3A4, but clinically significant CYP-mediated interactions are uncommon at standard doses.
MajorIsotretinoin / Vitamin A analogues
MechanismBoth agents independently raise intracranial pressure
EffectAdditive risk of pseudotumor cerebri with headache, papilloedema, and vision loss
ManagementContraindicated concurrently per Solodyn PI. Separate courses with appropriate washout.
FDA PI (Solodyn)MajorMethoxyflurane
MechanismTetracyclines potentiate nephrotoxicity of methoxyflurane
EffectFatal renal toxicity reported
ManagementAvoid concurrent use (FDA PI)
FDA PIMajorDivalent/Trivalent Cations (antacids, iron, calcium, Mg, Al)
MechanismChelation forms insoluble complexes reducing minocycline absorption
EffectReduced serum levels and potential treatment failure
ManagementSeparate dosing by at least 2–3 hours. Includes antacids, sucralfate, iron, calcium, and multivitamins containing minerals.
FDA PIModerateWarfarin / Oral Anticoagulants
MechanismTetracyclines may depress plasma prothrombin activity
EffectEnhanced anticoagulant effect with elevated INR and bleeding risk
ManagementReduce anticoagulant dose as needed; monitor INR frequently (FDA PI)
FDA PIModeratePenicillins
MechanismBacteriostatic tetracyclines may antagonise bactericidal penicillin action
EffectReduced penicillin efficacy, particularly relevant in meningitis and endocarditis
ManagementAvoid concurrent use when bactericidal activity is critical (FDA PI)
FDA PIModerateErgot Alkaloids
MechanismTetracyclines may increase risk of ergotism
EffectVasospasm and ischaemia
ManagementAvoid concurrent use (FDA PI)
FDA PIMinorOral Contraceptives
MechanismTheoretical alteration of GI flora affecting enterohepatic recirculation
EffectPossible reduced OC efficacy; evidence weak
ManagementSolodyn PI advises a second form of contraception during minocycline treatment
FDA PI (Solodyn)Monitoring
-
Hepatic Function
Baseline; periodically during long-term therapy; if symptoms arise
Routine AST, ALT, bilirubin. Minocycline has a higher hepatotoxicity risk than doxycycline, including autoimmune hepatitis and fulminant hepatic failure. Discontinue immediately if liver injury suspected. -
Autoimmune Markers (ANA)
If symptoms of autoimmune syndrome develop
Trigger-based Fever, arthralgia, rash, or myalgia during prolonged therapy should prompt ANA and LFT testing. Drug-induced lupus, autoimmune hepatitis, serum sickness, and vasculitis are all reported. Solodyn PI recommends periodic autoimmune lab evaluation. -
Renal Function (BUN, Cr)
Baseline; periodically during long-term therapy
Routine Tetracyclines have anti-anabolic effects that elevate BUN. Renal insufficiency may increase minocycline levels (unlike doxycycline). Dose reduction recommended if CrCl <80 mL/min. -
Skin / Mucosa Pigmentation
Each visit during prolonged (>3 month) therapy
Routine Examine skin (especially sun-exposed areas and scars), gums, nails, and sclera for blue-black or grey discoloration. If pigmentation develops, consider discontinuation as some changes may be irreversible. -
Thyroid Function
If on prolonged therapy (>6 months)
Trigger-based Brown-black thyroid discoloration and abnormal thyroid function have been reported. Thyroid cancer has been reported post-marketing. Consider thyroid monitoring with prolonged courses. -
Visual Symptoms
As needed
Trigger-based Headache with blurred vision, diplopia, or visual field loss may indicate intracranial hypertension. Discontinue and arrange ophthalmology assessment if suspected. -
INR (if on warfarin)
Within 3–5 days of starting
Trigger-based Minocycline may potentiate anticoagulant effect. Adjust warfarin dose as needed.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to minocycline or any tetracycline-class antibiotic
Relative Contraindications (Specialist Input Recommended)
- Pregnancy: Category D. Permanent tooth discoloration, enamel hypoplasia, inhibition of bone growth, and teratogenicity (skeletal malformations) in animals. Avoid unless no safer alternative exists.
- Children <8 years: Permanent tooth discoloration risk with repeated or prolonged courses. Use only for life-threatening infections (anthrax).
- Concurrent isotretinoin: Additive risk of pseudotumor cerebri. Solodyn PI states these should not be used together.
- Individuals attempting to conceive: Minocycline may impair spermatogenesis. Solodyn PI advises avoidance in patients of either gender attempting to conceive.
Use with Caution
- Renal impairment: Reduce total daily dose; PK not fully characterised; do not exceed 200 mg/day.
- Hepatic impairment: Greater hepatic metabolism than doxycycline; monitor LFTs. Fulminant hepatic failure reported.
- History of autoimmune disease: Minocycline can trigger drug-induced lupus, autoimmune hepatitis, and vasculitis.
- Patients requiring driving or operating machinery: Vestibular effects (dizziness, vertigo) are more common than with doxycycline.
- Lactation: Excreted in breast milk; calcium may limit infant absorption. Short courses probably safe; avoid prolonged use.
FDA Class-Wide Regulatory Warning
Tetracycline Class: Tooth Discoloration and Bone Growth Inhibition
The use of tetracycline-class drugs, including minocycline, during tooth development (last half of pregnancy, infancy, and childhood to age 8 years) may cause permanent discoloration of the teeth (yellow-grey-brown). Enamel hypoplasia has also been reported. Tetracyclines form a stable calcium complex in bone-forming tissue, and inhibition of linear bone growth has been documented in premature infants receiving oral tetracycline.
Patient Counselling
Purpose of Therapy
Minocycline is an antibiotic that works by stopping bacteria from growing. It is used to treat a range of infections and is also prescribed for inflammatory acne and rosacea due to its anti-inflammatory properties. Complete the full course as directed, even if symptoms improve early.
How to Take
Immediate-release capsules should be taken with a full glass of water, with or without food. Extended-release tablets (Solodyn, Emrosi) should be swallowed whole — do not crush, chew, or split them. Taking minocycline with food may reduce stomach upset. Avoid taking it at the same time as antacids, iron supplements, calcium, or multivitamins containing minerals; space them at least 2–3 hours apart.
Dizziness and Vertigo
Tell patientMinocycline can cause dizziness, light-headedness, or a spinning sensation (vertigo), especially in the first few days of treatment. This is more common with this antibiotic than with similar ones like doxycycline. Avoid driving or operating heavy machinery if affected.
Call prescriberIf dizziness or vertigo is severe, does not improve after the first week, or is accompanied by hearing changes or tinnitus.
Skin, Gum, or Nail Discoloration
Tell patientWith prolonged use, minocycline can cause blue-grey or dark discoloration of the skin, gums, nails, or whites of the eyes. Some of these changes may be permanent. Report any skin colour changes to your prescriber promptly.
Call prescriberIf you notice any unusual skin discoloration, darkening of the gums, or blue-grey patches on the skin, especially on the shins, face, or areas of old scars.
Signs of Autoimmune Reaction
Tell patientRarely, minocycline can trigger immune reactions that affect the joints, liver, or skin. These typically develop during prolonged treatment (more than a few weeks).
Call prescriberContact your prescriber immediately if you develop joint pain, unexplained fever, rash, muscle aches, yellowing of the eyes or skin, or unusual fatigue during treatment.
Stomach and Esophagus Irritation
Tell patientTake minocycline with a full glass of water and remain upright for at least 30 minutes. Taking with food may reduce nausea and stomach irritation.
Call prescriberIf you experience chest pain, difficulty swallowing, or vomiting blood.
Headache and Vision Changes
Tell patientHeadache is common with minocycline. However, a severe or worsening headache combined with visual changes could indicate a rare but serious increase in pressure inside the skull.
Call prescriberSeek urgent medical attention if you develop a severe headache with blurred or double vision, or any vision loss while taking minocycline.
Sources
Regulatory (PI / SmPC)
- MINOCIN (minocycline hydrochloride) Pellet-Filled Capsules — Full Prescribing Information. Revised 2010. accessdata.fda.gov Primary PI for immediate-release oral formulation with dosing for infections, STIs, meningococcal carrier state, and M. marinum.
- Solodyn (minocycline HCl) Extended Release Tablets — Full Prescribing Information. Revised 2011. accessdata.fda.gov Source for weight-based acne dosing, Phase 3 adverse event incidence data (headache, fatigue, dizziness, pruritus ≥5%), and autoimmune/pigmentation warnings.
- Emrosi (minocycline HCl) Extended-Release Capsules — Full Prescribing Information. Revised 2024. accessdata.fda.gov 40 mg ER capsule label for rosacea with sub-antimicrobial dosing rationale and safety data.
- MINOCIN IV (minocycline for injection) — Full Prescribing Information. Revised 2015. accessdata.fda.gov IV formulation label with dosing, thrombophlebitis warnings, and autoimmune syndrome descriptions.
Key Clinical Trials / Systematic Reviews
- Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329-1342. doi:10.1016/j.clinthera.2005.09.005 Head-to-head safety comparison from 24 doxycycline and 11 minocycline trials; minocycline associated with more AEs and higher AE reporting rates.
- Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;(8):CD002086. doi:10.1002/14651858.CD002086.pub2 Cochrane review of 39 RCTs (6,013 participants) concluding no proven superiority of minocycline over other acne antibiotics and a higher rate of adverse events.
- Torok HM. Extended-release formulation of minocycline in the treatment of moderate-to-severe acne vulgaris in patients over the age of 12 years. J Clin Aesthet Dermatol. 2013;6(7):19-22. PMC3718751 Review of Phase 2 and 3 Solodyn trials showing ER minocycline 1 mg/kg effective with vestibular AEs comparable to placebo (~9-10% vs 8-11%).
Guidelines
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. doi:10.1016/j.jaad.2015.12.037 AAD guideline recommending tetracyclines (including minocycline) as first-line systemic antibiotics for moderate-to-severe acne with combination topical therapy.
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(RR-4):1-187. doi:10.15585/mmwr.rr7004a1 CDC STI guidelines listing minocycline as alternative for chlamydial infections and syphilis in penicillin-allergic patients.
Mechanistic / Basic Science
- Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337-352. doi:10.1111/bph.12139 Comprehensive review of minocycline’s anti-inflammatory, neuroprotective, and immunomodulatory properties beyond antimicrobial activity.
- Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-265. doi:10.1016/j.jaad.2005.10.004 Review of MMP inhibition, anti-angiogenic, and anti-apoptotic properties underpinning dermatological applications.
- Nguyen F, Starosta AL, Arenz S, et al. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014;395(5):559-575. doi:10.1515/hsz-2013-0292 Detailed structural biology of tetracycline-30S ribosome interaction and resistance mechanisms (efflux pumps, ribosomal protection proteins).
Pharmacokinetics / Special Populations
- Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15(6):355-366. doi:10.2165/00003088-198815060-00001 Foundational PK review establishing minocycline bioavailability, half-life, protein binding, metabolism, and renal vs faecal elimination ratios.
- Lodise TP, Van Wart S, Sund ZM, et al. Pharmacokinetic and pharmacodynamic profiling of minocycline for injection following a single infusion in critically ill adults in a phase IV open-label multicenter study (ACUMIN). Antimicrob Agents Chemother. 2021;65(3):e01809-20. doi:10.1128/AAC.01809-20 Phase IV PK study in critically ill adults establishing median t½ of 20.3 h and characterising protein binding variability in the ICU population.